MRG006A treatment for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This two-part phase 1/2 interventional study tests MRG006A, an antibody–drug conjugate, in adults with advanced solid tumors. Phase 1 uses dose escalation to determine the maximum tolerated dose and recommended phase 2 dose while monitoring safety, pharmacokinetics, and immunogenicity. Phase 2 is a dose-expansion cohort at the confirmed dose to further measure tumor response by RECIST v1.1 (and mRECIST for HCC), safety, PK, and immunogenicity. Eligible patients must have measurable disease, ECOG 0–1, adequate organ function, and in some cases provide tumor tissue for GPC3 and P53 testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Understand and provide written informed consent and comply with the requirements set forth in the protocol.
2. age ≥ 18 years, ≤ 75 years.
3. Expected survival ≥ 3 months.
4. For patients with stage I and II disease, tumor tissue samples for GPC3 and P53 testing must be provided.
5. Patients with histologically or cytologically confirmed advanced solid tumors.
6. At least one measurable lesion according to RECISTv1.1 and mRECIST (HCC patients).
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
8. Organ function must meet basic requirements.
9. Women who are pregnant or breastfeeding are not included in this study.
10. Female and male patients of childbearing potential must agree to take adequate measures.

Exclusion Criteria:

1. Moderate and above thoracoabdominal pelvic fluid and pericardial effusion with clinical symptoms.
2. History of liver failure and hepatic encephalopathy.
3. Portal vein tumor thrombus involving both the main portal vein and left and right branches, or involving both the main portal vein and mesenteric vein needs to be excluded. The tumor involves the vena cava, or has formed a vena cava tumor thrombus.
4. Residual toxicity due to previous anti-tumor therapy or clinically significant laboratory abnormalities higher than grade 1 (CTCAEv5.0).
5. For liver cancer, previous or current central nervous system metastases and/or meningeal metastases. Patients with treated stable brain metastases from non-hepatic cancers may participate.
6. Patients at high risk of bleeding.
7. Severe cardiac insufficiency within 6 months prior to enrollment.
8. Pulmonary embolism or deep venous thrombosis within 3 months before the first study drug treatment;
9. History of gastrointestinal perforation, fistula, and bowel obstruction, extensive bowel resection, Crohn 's disease, ulcerative colitis, or chronic diarrhea for the past 6 months.
10. Patients with double cancer and multiple cancer.
11. Uncontrolled or poorly controlled disease.
12. History of ventricular tachycardia or torsades de pointes.
13. Previous or combined interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm and other medical history;
14. Allergic reactions to any component or excipient of MRG006A, or known Grade ≥ 3 allergic reactions to other prior anti-GPC3 or other monoclonal antibodies.
15. Acute or chronic active hepatitis B or C infection.
16. Active or clinically poorly controlled serious infection.
17. Receiving anti-tuberculosis treatment or receiving anti-tuberculosis treatment within 1 year before the first dose.
18. People infected with human immunodeficiency virus (HIV), known syphilis infection requiring treatment.
19. Use of systemic corticosteroids within 4 weeks prior to first treatment.
20. Use of strong CYP3A4 inducers, strong CYP3A4 inhibitors within 14 days or 5 times the half-life prior to the first dose.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• Zhongshan Hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jian Zhou, M.D. — Fudan University
• Study coordinator: Program Director
• Email: clinicaltrials@miracogen.com.cn
• Phone: 86-21-61637960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• MK-2010 alone or with other treatments for advanced solid tumors

  This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.

  Recruiting at 7 sites Phase 2 Merck Sharp & Dohme LLC · Belleville, New Jersey and 6 other locations · NCT07793942

• Whole-Body Infrared Heating for Advanced Solid Tumors

  This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.

  Recruiting Zhejiang Hospital · Hangzhou, Zhejiang · NCT07793214

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.